Newron Pharmaceuticals: EKF 2023 QuickView


Newron Pharmaceuticals: EKF 2023 QuickView

Key evenamide readouts on the horizon

Soo Romanoff

Written by

Soo Romanoff

Managing Director - Head of Content, Healthcare

Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central nervous system. The company’s marketed product, Xadago (or safinamide), is an add-on therapy to levodopa for the management of Parkinson’s disease, and continues to drive top-line revenues.

Read the full profile here.

Newron Pharmaceuticals is attending the 2023 Deutsches Eigenkapitalforum conference. If you would like to meet them, please email or register at


October insight: Still positive on bonds

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free